Literature DB >> 6466215

Nebulized gentamicin in children and adolescents with cystic fibrosis.

P Kun, L I Landau, P D Phelan.   

Abstract

A study of 29 children and adolescents with cystic fibrosis over 2 years showed some evidence of benefit from the twice daily inhalation of 20 mg nebulized gentamicin when compared to the inhalation of a nebulized saline mixture. Clinical symptoms, deterioration in pulmonary function, antibiotic usage, days in hospital and development of Pseudomonas aeruginosa in the sputum were recorded. There was no significant difference in antibiotic usage, days in hospital or clinical symptoms between the two regimes. Those subjects with P. aeruginosa in sputum showed significantly less deterioration in lung function over 2 years while using gentamicin aerosol. There was no difference in progress between the two treatment regimes for those subjects with P. aeruginosa in sputum at the beginning of the study, nor was there any difference in the number developing P. aeruginosa in sputum.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6466215     DOI: 10.1111/j.1440-1754.1984.tb00035.x

Source DB:  PubMed          Journal:  Aust Paediatr J        ISSN: 0004-993X


  18 in total

1.  Is prolonged rotavirus infection a common cause of protracted diarrhoea?

Authors:  M Sood; I W Booth
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Evidence for using nebulised antibiotics in cystic fibrosis.

Authors:  S P Conway
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

Review 3.  An overview of the management of cystic fibrosis.

Authors:  J M Littlewood
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

Review 4.  Clinical applications of pulmonary delivery of antibiotics.

Authors:  Patrick A Flume; Donald R VanDevanter
Journal:  Adv Drug Deliv Rev       Date:  2014-10-22       Impact factor: 15.470

5.  Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.

Authors:  D J Touw; F A Jacobs; R W Brimicombe; H G Heijerman; W Bakker; D D Briemer
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 6.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

Review 7.  Nebulized antibiotics in cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Yann Le Cocguic; Agnés Ferroni; Marlène Clairicia; Joel Barthe; Jan-Pierre Delaunay; Valentine Brousse; Gérard Lenoir
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.

Authors:  S Mukhopadhyay; M Singh; J I Cater; S Ogston; M Franklin; R E Olver
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

9.  Computer-assisted documentation of the clinical course of cystic fibrosis patients.

Authors:  B Tümmler; H von der Hardt
Journal:  Infection       Date:  1987       Impact factor: 3.553

10.  Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.

Authors:  Freddy Frost; Matthew Shaw; Dilip Nazareth
Journal:  Cochrane Database Syst Rev       Date:  2019-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.